Pathogenesis of Type 2 Diabetes

Slide 1 · Pathogenesis of Type 2 Diabetes

Genetic susceptibility, environmental exposures, and metabolic failure

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why genetic susceptibility alone does not determine disease expression.

Trace obesity-related insulin resistance to impaired glucose homeostasis.

Describe the transition from β-cell compensation to relative insulin deficiency.

Integrate inflammation, lipid excess, and clinical phenotypes into one causal model.

Slide 3 · Type 2 diabetes is a multifactorial disorder

Inherited and acquired influences

Susceptibility, obesity, inactivity and circadian disruption

Metabolic disturbances

Insulin resistance, lipid excess and inflammatory signaling

Inadequate β-cell response

Insulin supply fails to meet demand; Hyperglycemia develops

The pathways interact and do not imply one obligatory sequence for all patients.

Slide 4 · Hyperglycemia requires interacting defects

Insulin resistance

Target tissues respond inadequately to insulin; Demand for insulin rises.

β-cell dysfunction

Insulin secretion becomes insufficient for the prevailing resistance and glucose burden.

Resistance commonly appears first; Failure of compensation allows persistent hyperglycemia.

Slide 5 · Type 2 differs fundamentally from type 1 diabetes

Type 1 diabetes

Islet-directed autoimmune injury

Progressive loss of insulin-producing β-cells

Autoantibodies may identify presymptomatic disease

Type 2 diabetes

No established autoimmune basis in this account

Insulin resistance and inadequate β-cell compensation

Genetic, metabolic and inflammatory mechanisms

Proinflammatory mechanisms in T2D do not make it an autoimmune disease.

Slide 6 · Three interacting causal domains

Inherited predisposition

Polygenic variants affect adiposity and β-cell function.

Acquired exposures

Central adiposity, inactivity and circadian disruption.

Metabolic inflammation

Lipid excess and cytokines weaken insulin action and islet function.

None is a complete explanation in isolation.

Slide 7 · Familial aggregation indicates inherited susceptibility

5–10×

Higher risk in first-degree relatives (age- and weight-matched)

The textbook uses familial clustering as evidence for genetic contribution, not proof of a single-gene cause.

Slide 8 · Twin concordance supports a strong genetic component

>90%

Reported concordance in monozygotic twins

Concordance is not the same as genetic determinism; Shared environments can contribute.

Slide 9 · Type 2 diabetes usually has a polygenic basis

Many susceptibility alleles

Individually small-to-modest effects

Combined inherited liability

Vulnerability to acquired exposures

Common variants act together rather than following a simple Mendelian pattern.

Slide 10 · Genome-wide association studies identify risk loci

≥30

Loci reported in the source text

Many associated loci with individually minimal to modest lifetime-risk contributions; This is an edition-specific statement, not a current locus census.

Slide 11 · Risk loci implicate several biological systems

Adipose tissue

Body-fat distribution and metabolic behavior.

Pancreatic islets

β-cell function and insulin secretion.

Energy balance

Obesity susceptibility.

Genetic associations converge on mechanisms rather than one universal defect.

Slide 12 · Fat distribution is partly genetically influenced

Inherited variants

Affect adipose-tissue biology

Fat distribution

Visceral vs subcutaneous

Insulin sensitivity

Different metabolic consequences

Inherited variation can influence where excess adipose tissue is deposited.

Slide 13 · β-cell biology is an inherited vulnerability

β-cell–related variants

Influence insulin secretory capacity

Increased insulin demand

Triggered by resistance

Variable compensation

Determines glucose tolerance

Many risk polymorphisms affect insulin secretion, not simply body weight.

Slide 14 · A family history is a risk indicator—not a diagnosis

What family history supports

Higher prior probability of T2D

Shared genetic and environmental liability

Attention to modifiable exposures

What it does not establish

A single causative mutation

Current insulin resistance or hyperglycemia

Inevitable future diabetes

Separate predisposition from the phenotype.

Slide 15 · Genetic predisposition meets the environment

Two causal dimensions

Susceptibility

Inherited propensity to adiposity or β-cell stress

Exposure

Adiposity, inactivity, sleep/circadian disruption

Expression

Insulin resistance with inadequate compensation

A conceptual interaction model; No numerical risk estimates are implied.

Slide 16 · Central obesity is the major acquired risk factor

Visceral fat

More closely associated with insulin resistance than peripheral adiposity

Obesity—particularly central or visceral obesity—is the leading acquired T2D risk factor described here.

Slide 17 · Fat distribution matters beyond body mass index

Visceral/central adiposity

Greater lipolytic activity

Higher free fatty acid flux

Stronger association with insulin resistance

Predominantly subcutaneous adiposity

Different depot physiology

May confer comparatively lower metabolic risk

BMI alone cannot identify this pattern

The two fat compartments are not interchangeable.

Slide 18 · Body mass index is an imperfect metabolic proxy

Body mass index approximates overall adiposity, not its location.

Central adipose accumulation can carry risk not reflected by BMI alone.

The source describes individuals with T2D despite lacking overt generalized obesity.

Risk assessment must consider fat distribution and metabolic context.

Slide 19 · Metabolically important adiposity may be concealed

No overt obesity

Appearance or BMI may mislead

Visceral adiposity

Can still be increased

Insulin resistance

Metabolic dysfunction may follow

This phenotype in some Asian and Middle Eastern populations.

Slide 20 · Weight loss can improve insulin action

Reduced excess adiposity

Dietary modification and weight loss

Lower metabolic burden

Improved tissue insulin responsiveness

Better glucose tolerance

Particularly early in disease

The source reports benefit even with modest weight reduction; No specific threshold is provided.

Slide 21 · Physical inactivity acts independently of obesity

Low physical activity

Independent acquired T2D risk factor

Lower insulin responsiveness can occur without obesity

Contributes to metabolic vulnerability

Exercise

Improves insulin sensitivity

Promotes GLUT4 translocation in muscle

Complements weight reduction

Exercise is not simply a weight-loss intervention.

Slide 22 · Exercise alters muscle glucose transport

Muscle activity

Exercise-related signaling

GLUT4 translocation

More transporters at cell surface

Greater glucose uptake

Improved insulin sensitivity

This is one exercise-related mechanism.

Slide 23 · Weight loss and exercise have additive benefits

Weight reduction

Improves resistance related to excess adiposity.

Physical activity

Improves muscular glucose handling.

Combined approach

May yield additive gains in insulin sensitivity.

This mechanistic complementarity underlies early lifestyle intervention.

Slide 24 · Metabolic syndrome clusters related abnormalities

Central obesity

Visceral adipose burden

Hyperglycemia

Disordered glucose homeostasis

Dyslipidemia

Elevated cholesterol / triglycerides

Hypertension

Associated vascular risk

The source groups these features under metabolic syndrome; Diagnostic thresholds are not specified here.

Slide 25 · Sleep and circadian disruption contribute to risk

Sleep disorders

Obstructive sleep apnea is an example.

Shift work

Behavioral schedule can conflict with endogenous timing.

Restricted sleep

Nighttime sleep and daytime wakefulness become misaligned.

These are additional risks beyond adiposity and inactivity.

Slide 26 · Circadian misalignment perturbs glucose regulation

Circadian disruption

Internal rhythms vs behavior

Insulin secretion

May be impaired

Insulin action

May be impaired

Glucose homeostasis

Net dysregulation

Robbins also reports genetic associations involving circadian-regulated genes.

Slide 27 · Acquired risks converge on common physiology

Exposures

Central adiposity, inactivity and disrupted circadian timing

Intermediate mechanisms

Altered lipid flux, inflammatory mediators and glucose handling

Metabolic consequences

Insulin resistance with increased β-cell demands

Circadian disruption can also interfere directly with insulin secretion.

Slide 28 · Insulin resistance often appears before diabetes

Early resistance

Reduced target-tissue response

β-cell compensation

Increased insulin output

Compensatory limit

Insulin becomes inadequate

Overt T2D

Persistent hyperglycemia

A conceptual sequence, not a measured time scale.

Slide 29 · Early β-cell compensation preserves euglycemia

Insulin sensitivity falls

Higher demand per unit of glucose

β-cells secrete more

Compensatory hyperinsulinemia

Glucose remains controlled

Initially adequate compensation

Hyperinsulinemia can coexist with normal glucose tolerance early on.

Slide 30 · Relative insulin deficiency drives progression

Sustained insulin resistance

Insulin demand stays elevated

Inadequate β-cell adaptation

Secretion cannot meet demand

Persistent hyperglycemia

Functional transition to T2D

“Relative deficiency” means too little insulin for the metabolic need—not necessarily absent insulin.

Slide 31 · Insulin resistance affects three major tissues

Liver

Failure to suppress glucose output.

Skeletal muscle

Reduced postprandial glucose disposal.

Adipose tissue

Failure to suppress lipolysis.

These abnormalities explain different aspects of glucose dysregulation.

Slide 32 · Hepatic resistance elevates fasting glucose

Insulin signaling attenuated

Liver fails to respond normally

Gluconeogenesis persists

Endogenous glucose production rises

Fasting hyperglycemia

Glucose output remains excessive

Insulin normally suppresses hepatic glucose production.

Slide 33 · Muscle resistance elevates post-meal glucose

Meal supplies glucose

Insulin response is generated

Muscle uptake blunted

Less GLUT4-dependent transport

Postprandial glucose rises

Peripheral disposal is impaired

Skeletal muscle is a major insulin-responsive site for glucose uptake.

Slide 34 · Adipose resistance releases excess fatty acids

Insulin anti-lipolysis weakens

Hormone-sensitive lipase less suppressed

Triglycerides are mobilized

Adipocyte lipolysis increases

Plasma FFAs rise

Fuel excess reaches other tissues

Insulin resistance in fat can amplify resistance elsewhere.

Slide 35 · Insulin signaling can fail before glucose transport

Reduced receptor/IRS tyrosine phosphorylation

Attenuated insulin signaling

Less effective GLUT4 translocation

Reduced cellular glucose uptake

A functional signaling defect; Not necessarily a mutation of the insulin receptor.

Slide 36 · GLUT4 connects signaling to muscle uptake

Effective insulin action

Receptor/IRS signaling proceeds

GLUT4 increases at plasma membrane

Muscle glucose uptake increases

Insulin resistance

Receptor/IRS signaling is attenuated

Surface GLUT4 is reduced

Muscle glucose uptake is diminished

GLUT4 is a transporter response, not an insulin receptor.

Slide 37 · Visceral fat increases free-fatty-acid exposure

Central adipose tissue

Relatively high lipolytic activity

FFA release

More circulating lipid substrates

Insulin-responsive organs

Liver, muscle and β-cells affected

The textbook links central fat distribution to excess FFA supply.

Slide 38 · Intracellular lipid intermediates disrupt signaling

FFA overload

Oxidation capacity is exceeded

Lipid intermediate accumulation

DAG and ceramides, among others

Impaired insulin action

Signaling is attenuated

This is the lipotoxic signaling framework; Diagrams are conceptual.

Slide 39 · Fatty acids influence glucose use by two routes

Direct tissue effect

Lipid intermediates impair insulin signaling

Reduced insulin-stimulated glucose uptake

Competition between fuels for oxidation

Indirect inflammatory effect

Lipid excess activates inflammatory pathways

Cytokines promote resistance

β-cell dysfunction may also increase

A single upstream exposure has multiple downstream effects.

Slide 40 · Hepatic lipid excess can amplify glucose output

FFA influx and lipid intermediates

Excess substrate / cellular stress

Hepatic insulin resistance

Less suppression of gluconeogenesis

Increased endogenous glucose

Higher fasting glucose

The source also discusses enhanced phosphoenolpyruvate carboxykinase activity.

Slide 41 · Adipose tissue functions as an endocrine organ

Stored substrate

Triglyceride mobilization supplies FFAs.

Hormonal signals

Adipokines regulate systemic metabolism.

Immune signals

Inflammatory mediators act on target organs.

Adipose expansion changes signaling, not just energy storage.

Slide 42 · Adiponectin ordinarily supports insulin sensitivity

Obesity

Associated with lower adiponectin

Reduced adiponectin

Less insulin-sensitizing hormonal input

Insulin resistance

One contributing mechanism

Adiponectin itself ordinarily promotes peripheral insulin sensitivity.

Slide 43 · Adipokines have heterogeneous metabolic effects

Insulin-sensitizing example

Adiponectin decreases blood glucose

Partly improves insulin responsiveness

Often reduced with obesity

Other adipose signals

Some promote hyperglycemia

Multiple endocrine and cytokine outputs

Net effects depend on signal balance

Avoid describing all adipokines as either harmful or protective.

Slide 44 · Metabolic inflammation is not autoimmunity

Type 2 inflammatory milieu

Nutrient and lipid excess

Macrophage/islet cytokine signaling

Tissue insulin resistance and β-cell stress

Type 1 autoimmune injury

Loss of immune tolerance

Islet-reactive lymphocyte mechanisms

Destructive immune injury to β-cells

The pathogenesis and targets differ despite inflammatory components in both.

Slide 45 · Excess nutrients promote cytokine production

Excess FFAs and glucose

Nutrient stress

Cellular inflammatory responses

Macrophages and islet cells

Proinflammatory cytokines

Signaling to insulin-responsive tissues

This mechanism contributes to both resistance and secretory dysfunction.

Slide 46 · Inflammasome activation can increase IL-1β

Intracellular lipid overload

In macrophages and β-cells

Inflammasome activation

Cytoplasmic multiprotein complex

Interleukin-1β secretion

Amplifies local inflammation

IL-1β is an inflammatory mediator, not a specific diagnostic marker of T2D.

Slide 47 · Cytokines extend a local signal systemically

IL-1β and related signals

Proinflammatory cascade

Additional cytokine release

Macrophages and islet cells

Peripheral tissue resistance

Liver, fat and muscle response worsens

Inflammation constitutes an amplification pathway rather than the only cause.

Slide 48 · Lipid excess and inflammation reinforce each other

Visceral lipid excess

FFAs and metabolites

Inflammatory activation

IL-1β and cytokines

Insulin resistance

Impaired tissue response

Adipose lipolysis

Additional FFAs released

Conceptual feedback: Resistance can increase lipolysis and sustain lipid excess.

Slide 49 · Fatty liver belongs to the metabolic network

High circulating FFAs

Liver receives lipid substrate

Hepatocyte steatosis

MASLD spectrum

Metabolic dysregulation

Common with T2D/metabolic syndrome

MASLD is an associated phenotype; Do not mistake it for a required diagnostic criterion.

Slide 50 · Insulin resistance alone does not explain overt T2D

Compensated resistance

Insulin demand is high

β-cell secretion increases

Glucose tolerance can be maintained

Overt type 2 diabetes

Insulin demand remains high

β-cell response becomes inadequate

Chronic hyperglycemia develops

β-cell dysfunction is necessary for the usual progression.

Slide 51 · β-cell compensation has finite capacity

Demand increases

Peripheral resistance

Insulin output rises

Compensation

Reserve becomes insufficient

Functional failure

Relative deficiency

Persistent hyperglycemia

This is not a claim that insulin secretion necessarily reaches zero.

Slide 52 · Free fatty acids also impair β-cell function

Excess FFAs

Chronic substrate burden

β-cell lipotoxicity

Functional cellular stress

Insulin release impaired

Compensation becomes less effective

Lipotoxicity can affect insulin action and insulin secretion.

Slide 53 · Chronic hyperglycemia can worsen secretion

Glucose remains elevated

Persistent metabolic exposure

Glucotoxic stress

β-cell dysfunction

Inadequate insulin output

Further hyperglycemia

The source identifies glucotoxicity as a mechanism associated with β-cell dysfunction.

Slide 54 · An abnormal incretin effect is implicated

Gut-derived signals

GIP and GLP-1 augment meal-related insulin release.

Disordered incretin axis

Abnormal incretin effects with impaired compensation.

Functional outcome

Less appropriate insulin secretion for a glucose challenge.

Mechanistic overview only; No quantitative hormone-response claim.

Slide 55 · Islet amyloid is a characteristic association

Observed in longstanding T2D

Amyloid accumulates within islets

Associated with β-cell dysfunction

Prominent in source discussion

Unresolved direction of causation

Might contribute to cell failure

Might reflect preceding β-cell injury

Association alone does not establish causality

Whether islet amyloid causes or follows β-cell dysfunction remains unresolved.

Slide 56 · Genetic variation also influences secretory reserve

Inherited β-cell susceptibility

Risk-related gene variation

Chronic resistance-related demand

Higher insulin needs

Variable β-cell adaptation

Influences progression to T2D

β-cell capacity and tissue resistance are jointly consequential.

Slide 57 · Multiple β-cell stresses converge

Lipotoxicity

Excess fatty acids

Glucotoxicity

Chronic hyperglycemia

Incretin abnormalities

Less effective meal-linked insulin response

Islet amyloid

Longstanding association; Causality uncertain

Inherited vulnerability modifies this combined stress response.

Slide 58 · From visceral obesity to diabetes: A causal synthesis

Visceral adiposity and nutrient excess

FFAs / adipokines / inflammatory mediators

Insulin resistance with higher secretory demand

β-cell compensation becomes inadequate

Sustained hyperglycemia

Schematic assembly from the textbook, not a single obligatory pathway.

Slide 59 · Fasting and postprandial glucose reflect different defects

Predominantly fasting elevation

Insulin fails to suppress liver glucose production

Continued gluconeogenesis

Hepatic resistance is a major contributor

Predominantly post-meal elevation

Insulin-stimulated muscle uptake is impaired

Less glucose disposal after eating

Secretory reserve also affects the response

Both patterns can coexist in the same patient.

Slide 60 · Phenotypic expression varies across individuals

Mechanism-to-phenotype examples

Central adiposity

Increased FFA flux and insulin resistance

High insulin with normal glucose

Early successful β-cell compensation

Persistent hyperglycemia

Compensation no longer adequate

Steatotic liver

Parallel manifestation of lipid/metabolic stress

Mechanism-based interpretation, not a clinical diagnostic algorithm.

Slide 61 · Clinical scenario: Hyperinsulinemia without diabetes

Clinical vignette

An adult with central adiposity has evidence of insulin resistance, increased circulating insulin, but glucose measurements remain within the normal range.

Why can glucose remain normal despite resistance?

β-cell compensation raises insulin secretion sufficiently to meet increased demand—until this adaptive capacity becomes inadequate.

Slide 62 · Clinical scenario: Diabetes without marked obesity

Clinical vignette

An adult without obvious generalized obesity develops elevated fasting and postprandial glucose. Imaging or clinical assessment suggests increased central adiposity.

Which misconception should be avoided?

Low apparent overall adiposity does not exclude visceral fat accumulation or insulin resistance; β-cell secretory vulnerability may coexist.

Slide 63 · Three common causal misconceptions

“T2D is autoimmune”

No evidence of an autoimmune basis in this source.

“Obesity is sufficient”

Progression also requires inadequate β-cell adaptation.

“Normal BMI excludes risk”

Visceral fat and inherited susceptibility can remain relevant.

Correctly separating risk, mechanism and disease is essential.

Slide 64 · Integrated pathogenesis: Four central conclusions

Polygenic susceptibility changes how adiposity and β-cells respond to metabolic demand.

Visceral adiposity, inactivity and circadian disruption increase acquired risk.

Resistance in liver, muscle and adipose tissue generates distinct metabolic consequences.

Chronic hyperglycemia appears when β-cell secretion no longer compensates adequately.

Slide 65 · Primary reading and source boundaries

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. 2026. Chapter 24, The Endocrine System.

Primary topic: “Pathogenesis of Type 2 Diabetes,” p. 1003; subheadings “Genetic Factors” and “Environmental Factors.”

Mechanistic expansion from adjacent section: “Metabolic Defects in Type 2 Diabetes,” pp. 1003–1004.

Conceptual diagrams were newly constructed as editable PowerPoint elements; no original pathology figures were reproduced.